mBio (Oct 2021)
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs
- Jesús Horacio Lara-Puente,
- Juan Manuel Carreño,
- Weina Sun,
- Alejandro Suárez-Martínez,
- Luis Ramírez-Martínez,
- Francisco Quezada-Monroy,
- Georgina Paz-De la Rosa,
- Rosalía Vigueras-Moreno,
- Gagandeep Singh,
- Oscar Rojas-Martínez,
- Héctor Elías Chagoya-Cortés,
- David Sarfati-Mizrahi,
- Ernesto Soto-Priante,
- Constantino López-Macías,
- Florian Krammer,
- Felipa Castro-Peralta,
- Peter Palese,
- Adolfo García-Sastre,
- Bernardo Lozano-Dubernard
Affiliations
- Jesús Horacio Lara-Puente
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Juan Manuel Carreño
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Weina Sun
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Alejandro Suárez-Martínez
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Luis Ramírez-Martínez
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Francisco Quezada-Monroy
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Georgina Paz-De la Rosa
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Rosalía Vigueras-Moreno
- Diagnósticos Clínicos Veterinarios, S. A. de C. V. (DCV), Iztapalapa, CDMX, Mexico
- Gagandeep Singh
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Oscar Rojas-Martínez
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Héctor Elías Chagoya-Cortés
- Consultora Mextrategy, S. A. S. de C. V., Benito Juárez, CDMX, Mexico
- David Sarfati-Mizrahi
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Ernesto Soto-Priante
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Constantino López-Macías
- Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social (IMSS), Cuauhtémoc, CDMX, Mexico
- Florian Krammer
- ORCiD
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Felipa Castro-Peralta
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- Peter Palese
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Adolfo García-Sastre
- ORCiD
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Bernardo Lozano-Dubernard
- Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico
- DOI
- https://doi.org/10.1128/mBio.01908-21
- Journal volume & issue
-
Vol. 12,
no. 5
Abstract
Several highly efficacious vaccines for SARS-CoV-2 have been developed and are used in the population. However, the current production capacity cannot meet the global demand. Therefore, additional vaccines—especially ones that can be produced locally and at low cost—are urgently needed. This work describes preclinical testing of a SARS-CoV-2 vaccine candidate which meets these criteria.
